In the rush to stake a claim in next-generation mental health treatments, biotech headlines are dominated by billion-dollar acquisitions and bold clinical projections. But in the fine print—in courtrooms, patent filings, and regulatory footnotes—a quieter battle is unfolding. And it’s one that could have just as much bearing on who owns the future of psychedelic-inspired therapeutics.
Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being tested, as Gilgamesh Pharmaceuticals moves to challenge Enveric’s patent claims, just weeks after AbbVie announced its $1.2 billion acquisition of Gilgamesh’s lead compound, Bretisilocin (GM-2505).
The IP at the Center of the Storm
The dispute centers around U.S. Patent No. 12,138,276, a granted Enveric patent covering halogenated psilocybin derivatives and, crucially, claims that appear relevant to the chemical space around Bretisilocin. Rather than backing down, Enveric has done the opposite: it has retained Fish & Richardson P.C., a heavyweight law firm with deep biotech IP experience, to contest Gilgamesh’s post-grant review (PGR) petition.
While the ’276 patent doesn’t cover Enveric’s lead candidate EB-003, it remains a strategically valuable asset within a larger IP estate that includes:
-
26 issued U.S. patents
-
60+ pending applications in markets including Europe, China, Japan, and Canada
-
Multiple programs protected across five distinct patent families
Meanwhile, Enveric Builds for the Long Game
This is not a company defined by a single molecule.
Enveric’s internal pipeline includes:
-
EB-003, a dual 5-HT2A/5-HT1B agonist designed to deliver psychedelic-like neuroplasticity without the hallucinations, on track for IND submission in early 2026
-
The EVM-401 series, discovered via Enveric’s Psybrary™ platform, which has yielded over 1,500 novel structures
-
Three partnered programs, out-licensed to third parties, with Enveric eligible for up to $205 million in milestone payments and royalties
In other words, this isn’t a company clinging to a single IP asset, it’s a biotech platform poised to scale.
What This Means for the Sector
AbbVie’s acquisition of Bretisilocin wasn’t just a vote of confidence in psychedelic-inspired therapeutics, it was a signal that Big Pharma wants to own the space.
But in the fine print of that transaction, companies like Enveric are asserting a different kind of power: ownership of the intellectual framework behind the next wave of CNS innovation.
And if Enveric’s defense holds and if EB-003 reaches the clinic as planned, it will be a case study in what it looks like to play the long game in biotech: defend your IP, advance your science, and let the big bets come to you.
